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ENOblock inhibits the pathology of 
diet-induced obesity
Haaglim Cho1, Ji-Hyung Lee1, JungIn Um1, Sunwook Kim1, Yukyung Kim1, Woong-Hee Kim1, 
Yong Sook Kim2, Haushabhau S. Pagire3, Jin Hee Ahn3, Youngkeun Ahn2, Young-Tae Chang  4,5,  
Da-Woon Jung1 & Darren R. Williams1
Obesity is a medical condition that impacts on all levels of society and causes numerous comorbidities, 
such as diabetes, cardiovascular disease, and cancer. We assessed the suitability of targeting enolase, 
a glycolysis pathway enzyme with multiple, secondary functions in cells, to treat obesity. Treating 
adipocytes with ENOblock, a novel modulator of these secondary ‘moonlighting’ functions of enolase, 
suppressed the adipogenic program and induced mitochondrial uncoupling. Obese animals treated with 
ENOblock showed a reduction in body weight and increased core body temperature. Metabolic and 
inflammatory parameters were improved in the liver, adipose tissue and hippocampus. The mechanism 
of ENOblock was identified as transcriptional repression of master regulators of lipid homeostasis 
(Srebp-1a and Srebp-1c), gluconeogenesis (Pck-1) and inflammation (Tnf-α and Il-6). ENOblock 
treatment also reduced body weight gain, lowered cumulative food intake and increased fecal lipid 
content in mice fed a high fat diet. Our results support the further drug development of ENOblock as a 
therapeutic for obesity and suggest enolase as a new target for this disorder.
Enolase is an enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate, the ninth 
and penultimate step of the anciently conserved glycolysis pathway1. It is ubiquitously expressed in human cells 
and proteomic meta-analysis identified α-enolase as the second protein to be differentially expressed in human 
pathologies, implicating enolase as an indicator of tissue dysfunction in multiple diseases2. Enolase has many 
diverse, secondary ‘moonlighting’3 functions that are unrelated to its catalytic activity, such as binding plasmino-
gen (a key component of the fibrinolytic system) on the cell membrane, stabilizing the mitochondrial membrane, 
structural functions as a lens crystallin protein, and a repressor of gene expression in the nucleus1,4,5. Recently, 
we have developed the small molecule, ENOblock, as a chemical probe for elucidating the moonlighting func-
tions of enolase in biological assays4–7. ENOblock binds enolase at the dimerization domain and induces nuclear 
localization, where it acts as a transcriptional repressor6–8. In contrast, other glycolytic enzymes that moonlight in 
the nucleus, such as phosphofructokinase, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate 
kinase, activate gene expression9. ENOblock treatment increased enolase nuclear translocation in different cell 
types and was also effective in vivo, increasing enolase nuclear localization in mouse liver and kidney7. Previously, 
ourselves and others have used ENOblock to indicate non-glycolytic functions of enolase related to inflamma-
tion, cancer cell invasion/migration and glucose homeostasis6,7,10–12. Moreover, ENOblock treatment suppressed 
the expression of known enolase target genes, and produced anti-diabetic effects in a genetic model of diabetes7.
Obesity is a leading preventable cause of death and one of the most pressing health concerns of the 21st cen-
tury13. It is classified as a disease14, with increasing rates in adults and children15, and numerous comorbidities, 
such as insulin resistance16, type 2 diabetes17, hypertension18, cardiovascular disease19, some types of cancer19, 
osteoarthritis20, asthma21, obstructive sleep apnea22 and psychological disorders23. The main treatment for obesity 
is lifestyle management (dieting and increased physical activity) although maintaining long-term weight loss is 
frequently difficult to achieve, with success ranging from 2–20%24. Bariatric surgery is the most effective treat-
ment, but it is expensive and associated with complications25. Five medications are approved for the long-term 
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treatment of obesity in the United States: orlistat, lorcaserin, liraglutide, phentermine–topiramate, and naltrex-
one–bupropion26. Unfortunately, these may produce significant side effects, such as gastrointestinal problems 
with orlistat27, and their long term effects on obesity-related comorbidities are not established28. Therefore, it is 
necessary to develop new therapeutics and drug targets for treating obesity.
In light of the relative lack of effective medicines and targets for treating obesity compared to diseases such 
as type 2 diabetes, we tested the pharmacological targeting of enolase moonlighting with ENOblock in a model 
of diet-induced obesity, wherein animals are fed a highly palatable, Western-style diet rich in fats and sugar. 
ENOblock was compared with rosiglitazone, a thiazolidinedione class of drug that can reduce the symptoms of 
prediabetes, but not obesity, and subsequently metformin, which is the most commonly prescribed anti-diabetic 
drug for obese patients that can also produce anti-obesity effects29–31. Our results show that ENOblock produced 
dramatic improvements on numerous pathological parameters of obesity by repressing the transcription of mas-
ter regulators of adipogenesis, lipid homeostasis, inflammation and gluconeogenesis. These findings support the 
further development of ENOblock as a therapeutic for diet-induced obesity and implicate enolase as a novel 
target for treating this disorder.
Results
ENOblock treatment suppresses adipogenesis in differentiating white adipocyte and reduces 
mitochondrial membrane potential in white and brown adipocytes. To determine the potential 
of ENOblock as an anti-obesity therapeutic, the effect of this compound on adipogenesis-related gene expres-
sion was assessed by qPCR. The following genes were tested: adiponectin (Adipoq), adipocyte protein 2 (Ap2), 
peroxisome proliferator-activated receptor gamma (Ppar-γ), resistin (Retn), angiotensin (Agt), CCAAT/enhanc-
er-binding protein-α (Cebpa) and CCAAT/enhancer-binding protein-β (Cebpb). Some classes of compounds 
that show anti-obesity effects in animal models, such the β-3 adrenergic agonist CL 316,243, upregulate oxida-
tive phosphorylation or thermogenesis-related genes32,33. Therefore, genes regulating oxidative phosphorylation 
or thermogenesis were also assessed: (nuclear respiratory factor 1 (Nrf1), cytochrome c oxidase subunit VIIIb 
(Cox8b) and carnitine palmitoyltransferase I (Cpt1b)) or thermogenesis (uncoupling proteins 1–3 (Ucp-1, Ucp-2, 
Ucp-3), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc-1α) and PR domain contain-
ing 16 (Prdm16)).
As a first test, murine primary cultures of white preadipocytes were treated with ENOblock for 72 h (Fig. 1A). 
The effects on gene expression pattern was compared with preadipocytes treated with known compounds that 
enhance thermogenesis (forskolin34–36) or block adipogenesis (rapamycin37,38). After 72 h treatment, ENOblock 
treated preadipocytes showed no significant change in the expression of the adipogenesis regulatory genes, 
Adipoq, Ppar-γ, Cebpa and Cebpb, down-regulated expression of Ap2 and Agt, and upregulated expression of Retn 
(Fig. 1B). ENOblock treatment upregulated expression of the markers of oxidative phosphorylation, Cox8b and 
Cpt1b, and down-regulated Nrf1. The thermogenesis marker, Ucp-1 was upregulated after ENOblock treatment, 
whereas Prdm16 was down-regulated and Ucp-2, Ucp-3 and Pgc-1α showed no significant change in expression 
(Fig. 1C,D).
To assess the effect of ENOblock on the induction of adipogenesis, the preadipocytes were treated with 
ENOblock for 72 h, followed by adipogenic factors for 5 days (Fig. 1E–H). ENOblock treated cells showed signifi-
cant downregulation of the adipogenesis genes Adipoq, Ap2, Ppar-γ, Retn, Agt, Cebpa and Cebpb. Treatment with 
rapamycin produced downregulation of Adipoq, Ap2, Ppar-γ and Retn, but not Agt, Cebpa and Cebpb. ENOblock 
treatment upregulated the oxidative phosphorylation marker genes Nrf1 and Cox8b, and downregulated Cpt1b. 
ENOblock treatment increased expression of the thermogenesis marker, Ucp-3, but not Ucp-1, Prdm16 or Pgc-1α. 
Forskolin treatment increased expression of the markers Ucp-3 and Prdm16 (Ucp-2 expression was not detectable 
in the differentiating adipocytes using qPCR).
To investigate the effect of ENOblock on adipocytes in the process of adipogenesis, primary white adipo-
cytes were treated with adipogenic factors for 72 h, followed by ENOblock treatment for 5 days (Fig. 2A–D). For 
this test, the effect of ENOblock treatment was compared with NaF, an enolase enzyme inhibitor that, unlike 
ENOblock, does not induce enolase nuclear translocation7. ENOblock treatment inhibited expression of the adi-
pogenic genes Adipoq, Ap2, Ppar-γ, Retn, Agt, Cebpa and Cebpb. Treatment with NaF downregulated Adipoq, 
Ap2, Retn and Cebpa, but not Ppar-γ and Cebpb. Similar to ENOblock, rapamycin treatment also downregulated 
expression of all 7 adipogenesis-related genes. ENOblock down-regulated expression the oxidative phospho-
rylation markers Nrf1, Cox8b and Cpt1b, and upregulated expression of the thermogenesis marker, Ucp-1, but 
not Ucp-2, Ucp-3 and Prdm16. Forskolin treatment also upregulated Ucp-1 and down-regulated Nrf1, Cox8b 
and Cpt1b (Fig. 2C,D). NaF treatment down-regulated Cox8b and did not significantly influence expression of 
Nrf1, Cpt1b or Ucp-1. Overall, these results indicate that ENOblock is effective at blocking adipogenesis-related 
gene expression in white adipocytes undergoing differentiation. In differentiating adipocytes and preadipocytes, 
ENOblock treatment upregulated expression of the thermogenesis genes, Ucp-1, although there was no concom-
itant upregulation of genes regulating oxidative phosphorylation.
The effects of ENOblock treatment on adipogenesis, oxidative phosphorylation and thermogenesis was also 
tested in primary cultures of differentiating brown preadipocytes derived from brown adipose tissue (BAT) 
(Supplementary Fig. 3). The adipogenesis genes Adipoq, Ap2, Ppar-γ, Retn, Agt and Cebpa were not significantly 
affected by ENOblock treatment. Oxidative phosphorylation markers Nrf1 and Cpt1b were down-regulated by 
ENOblock and expression of the thermogenesis markers Ucp-1, Ucp-2 and Ucp-3 were not significantly affected 
(Supplementary Fig. 3A–D). This result indicates that ENOblock is more effective at blocking adipogenesis 
gene-related expression in white adipocytes compared to brown adipocytes.
Anti-obesity agents can induce thermogenesis in brown adipose tissue (BAT) and ‘browning’ of white adi-
pose tissue (WAT), which is detected as proton leak in the inner mitochondrial membrane33,39,40. 3T3-L1 white 
preadipocytes were treated with ENOblock, NaF, rapamycin, or forskolin. Mitochondrial membrane potential 
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(an indicator of proton leak in the inner mitochondrial membrane) was measured using tetramethylrhodamine, 
ethyl ester (TMRE, an indicator of mitochondrial membrane potential41). 3T3-L1 and brown preadipocytes 
treated with ENOblock for 72 h showed decreased membrane potential (Fig. 2E,F). The inhibitory effect of 
ENOblock on membrane potential was also confirmed in white primary preadipocytes using automated micros-
copy (Supplementary Fig. 3E,F). Treatment with forskolin or rapamycin also reduced membrane potential in 
the preadipocytes. NaF treatment did not reduce membrane potential. Based on this result, these compounds 
Figure 1. ENOblock effect on the induction of adipogenic gene expression in preadipocytes. (A) Schematic 
of the compound treatment protocol in primary WAT preadipocytes. (B) Effect of 72 h treatment with 
10 µM forsoklin, 1 µM rapamycin or 10 µM ENOblock on the expression of adipogenesis regulatory genes. 
(C) Expression of oxidative phosphorylation regulatory genes after compound treatment. (D) Expression of 
thermogenesis regulatory genes after compound treatment. (E) Schematic of the compound pre-treatment 
protocol in WAT preadipocytes undergoing adipogenic differentiation. (F) Effect of treatment with 10 µM 
forsoklin, 1 µM rapamycin or 10 µM ENOblock on the expression of adipogenesis regulatory genes in 
differentiating preadipocytes. (G) Expression of oxidative phosphorylation regulatory genes after compound 
treatment. (H) Expression of thermogenesis regulatory genes after compound treatment. The treatment 
concentrations of forskolin, rapamycin or ENOblock were based on the following references7,87,88. n = 9; ns: 
not significantly different. *, ** or ***: significantly different from the corresponding ‘Control’ or ‘Untreated’ 
respectively with p < 0.05, p < 0.01 or p < 0.001; ## or ###: significantly different from the corresponding 
‘ENOblock’, ж, жж or жжж: significantly different from the corresponding ‘Forskolin’.
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were further tested in primary cultures of BAT derived preadipocytes. In brown preadipocytes, ENOblock, 
rapamycin and forskolin, significantly reduced mitochondrial membrane potential (Fig. 2E–G). To confirm the 
ENOblock-mediated adipogenesis gene suppression inhibits adipogenesis, differentiating cultures of 3T3-L1 
white preadipocytes were treated with ENOblock, forskolin or rapamycin for 72 hours and adipogenic factors 
Figure 2. Influence of ENOblock on the adipogenic program in differentiating preadipocytes and 
mitochondrial membrane potential. (A) Schematic of the compound treatment protocol in primary cultures 
of differentiating white adipocytes. (B) Effect of 72 h treatment with 10 µM forsoklin, 1 µM rapamycin,10 µM 
ENOblock or 1 mM NaF on the expression of adipogenesis regulatory genes in differentiating adipocytes. (C) 
Expression of oxidative phosphorylation regulatory genes. (D) Expression of thermogenesis regulatory genes. 
(E) Live cell imaging of TMRE fluorescence to visualize mitochondrial membrane potential in 3T3-L1 white 
preadipocytes and brown preadipocytes after treatment with 10 µM ENOblock, 1 mM NaF, 10 µM forsoklin or 
1 µM rapamycin for 72 h. (F) Quantification of mitochondrial membrane potential in 3T3-L1 preadipocytes. (G) 
Quantification of mitochondrial membrane potential in brown preadipocytes. (H) Oil red O staining of 3T3-
L1 white preadipocytes treated with 10 µM ENOblock, 1 mM NaF, 10 µM forsoklin or 1 µM rapamycin for 72 h 
and adipogenic factors for 5 days. (I) Quantification of oil red O staining in the treated adipocytes. n = 9; ns: 
not significantly different. *, ** or ***: significantly different from the corresponding ‘Control’ or ‘Untreated’ 
respectively with p < 0.05, p < 0.01 or p < 0.001; ## or ###: significantly different from the corresponding ‘NaF’ 
sample with p < 0.01 or p < 0.001; ж, жж or жжж: significantly different from the corresponding ‘ENOblock’ 
sample respectively with p < 0.05, p < 0.01 or p < 0.001.
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for 5 days, and stained with Oil Red O to visualize lipid accumulation. Treatment with ENOblock or forskolin 
reduced lipid accumulation in the differentiating adipocytes (Fig. 2H,I).
In human hepatocytes treated with ENOblock, enolase was observed to accumulate in the nucleus 
(Supplementary Fig. 1A). This effect was not observed after rosiglitazone treatment. Although the exact mech-
anism of enolase nuclear translocation is unknown42, the O-GlcNAc modification has been reported on enolase 
and is linked to nuclear localization43,44. Treatment with OSMI-1 was shown to reduce enolase localization in 
the presence of ENOblock (Supplementary Fig. 1B). Inhibiting enolase nuclear import with OSMI-1 was also 
shown to reduce the effects of ENOblock on SREBP-1a, -1c and SREBP-2 expression (inserted as Supplementary 
Fig. 1D). Additionally, we observed that OSMI-1 treatment reduced the inhibitory effect of ENOblock on lipid 
accumulation in differentiating adipocytes (inserted as Supplementary Fig. 1C). OSMI-1 treatment also inhib-
ited the negative effect of ENOblock on SPREBP expression (Supplementary Fig. 1D). Moreover, siRNA medi-
ated silencing of enolase also inhibited the negative effect of ENOblock on SREBP expression (Supplementary 
Fig. 2A,B). Chromatin immunoprecipitation assay of the SREBP-1 and -2 upstream promoters indicated enolase 
direct binding, with a higher detection signal for the SREBP-2 promoter compared to SREBP-1 (Supplementary 
Fig. 2C).
ENOblock treatment reduces weight gain, recovers body temperature and prevents hypergly-
cemia in diet-induced obese mice. The chemical structure of ENOblock is shown in Fig. 3A. A schematic 
of the treatment protocol to investigate the effects of ENOblock in the high fat diet (HFD) induced model of 
obesity is shown in Fig. 3B. At the end of the 8 weeks’ drug treatment regime, ENOblock treated mice showed 
reduced body weight compared to their untreated or rosiglitazone-treated counterparts (Fig. 3C–E). During the 
8 weeks of drug treatment, weight gain in the ENOblock treated HFD mice was reduced compared to untreated 
and rosiglitazone-treated HFD mice (Fig. 3D,E). The reduction in body weight between ENOblock treated and 
untreated HFD mice achieved statistical difference after three weeks. After seven weeks of treatment, ENOblock 
HFD mouse body weight was not significantly different to mice fed a standard chow diet (SFD group) (Fig. 3E). 
Measurement of food intake showed no significant difference between the treatment groups (Fig. 3F). ENOblock 
treatment produced significantly elevated body temperature compared to untreated and rosiglitazone-treated 
mice, which became apparent at 6 weeks of drug treatment (Fig. 3G). The body temperature in ENOblock treated 
mice was not significant compared to the SFD mice at 6 weeks of drug treatment, whereas body temperature in the 
rosiglitazone-treated mice was significantly lower than SFD mice (Fig. 3G). ENOblock and rosiglitazone-treated 
mice showed significantly reduced fasted blood glucose level compared to HFD mice at 3, 5 and 7 weeks of drug 
treatment (Fig. 3H).
ENOblock treatment improved glucose-, insulin-, and pyruvate tolerance, and reduced hyper-
insulinemia in obese mice. Mice were subjected to a glucose tolerance test (GTT) at 4 weeks of treatment. 
ENOblock- and rosiglitazone-treated mice showed improved glucose tolerance compared to untreated HFD mice 
(Fig. 4A,B). An insulin tolerance test (ITT) was carried out after 5 weeks of drug treatment. Compared to HFD 
mice, ENOblock- and rosiglitazone-treated mice showed improved insulin tolerance, which was not significantly 
different to insulin tolerance in SFD mice (Fig. 4C,D). Hyperinsulinemia was also reduced in the ENOblock- and 
rosiglitazone-treated mice compared to HFD mice, along with a concomitant reduction in homeostatic model 
assessment – insulin resistance (HOMA-IR) (Fig. 4E,F). The pyruvate tolerance test (PTT) was administered after 
7 weeks of drug treatment. ENOblock- and rosiglitazone-treated HFD mice showed an improved blood glucose 
response after pyruvate challenge compared to the untreated HFD mice (Fig. 4G–H). Blood glucose level after 
PTT showed no statistical significance between SFD mice and the ENOblock-treated or rosiglitazone-treated 
HFD mice.
ENOblock treatment prevents steatosis and fibrosis in the liver of obese mice. Photographs 
of representative, dissected liver tissue from the HFD mice after 8 weeks of ENOblock treatment are shown in 
Fig. 5A. HFD and rosiglitazone treated mice showed visibly paler patches on the liver tissue compared to SFD 
and ENOblock-treated HFD mice. ENOblock-treated HFD mice had significantly smaller liver weight compared 
to the HFD and SFD mice (Fig. 5B). A serum alanine aminotransferase (ALT) assay was carried out to assess 
potential hepatotoxicity caused by ENOblock treatment. Untreated HFD and rosiglitazone-treated HFD mice 
showed significantly elevated serum ALT compared to SFD mice at 8 weeks of drug treatment. ALT level in the 
ENOblock-treated mice was not significantly elevated compared to the SFD mice (Fig. 5C).
Oil red O staining was used to assess liver lipid accumulation. HFD mice showed significant lipid accumu-
lation compared to SFD mice, which was inhibited by ENOblock treatment (Fig. 5D,E). Rosiglitazone treat-
ment did not reduce lipid accumulation. H&E staining indicated that HFD mice developed liver microsteatosis 
(Fig. 5F,G). ENOblock treatment reduced microsteatosis, whereas rosiglitazone treatment had no significant 
effect (Fig. 5F,G). Masson’s Trichrome staining showed the significant development of liver fibrosis in HFD 
mice. ENOblock treatment, but not rosiglitazone, reduced fibrosis to the level observed in SFD mice (Fig. 5H,I). 
The development of liver fibrosis by diet-induced obesity is associated with the activation of hepatic stellate 
cells, which can be detected by immunostaining for alpha smooth muscle actin (α-SMA)45. HFD mice showed 
increased levels of hepatic stellate cells compared to SFD mice. ENOblock, but not rosiglitazone, reduced stellate 
cell numbers to the level observed in the SFD mice (Fig. 5J,K). The ability of ENOblock to reduce the develop-
ment of fibrosis in the liver of HFD mice was confirmed by qPCR and western blot analysis of α-SMA expression 
(Fig. 5L and Supplementary Fig. 4).
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Figure 3. Effect of ENOblock treatment on visceral fat, weight, body temperature and fasted glucose level in 
obese mice. (A) Chemical structure of ENOblock. (B) Schematic of the ENOblock treatment protocol in HFD 
mice. (C) Photograph showing the overall effect of 8 weeks treatment with ENOblock or rosiglitazone in HFD 
mice. (D) Photograph of the dissected abdomen showing visceral fat tissues in the treated mice (indicated with 
white arrows). (E) Effect of ENOblock or rosiglitazone treatment on body weight in HFD mice. n = 6. (F) Food 
intake in the treated mice. n = 6. (G) Body temperature of the mice during drug treatment. n = 6. (H) Fasted 
blood glucose level in the sera of HFD mice after 4, 6, and 8 weeks treatment with ENOblock or rosiglitazone. 
SFD = mice fed standard chow; HFD = high fat diet-fed mice; HFD-ENO = ENOblock treated HFD mice; 
HFD-Rosi = rosiglitazone treated HFD mice. n = 6; ns: not significantly different. *, ** or ***: significantly 
different from the corresponding ‘SFD-Normal’ or ‘SFD-Control’ (Standard Fat Diet-none-treated normal 
healthy mouse group) respectively with p < 0.05, p < 0.01 or p < 0.001; ## or ###: significantly different from the 
corresponding ‘HFD-none’ or ‘HFD-Control’ (HFD-non-treated control mouse group) sample with p < 0.01 or 
p < 0.001; ж, жж or жжж: significantly different from the corresponding ‘HFD-Rosi’ sample respectively with 
p < 0.05, p < 0.01 or p < 0.001. The copyright holder (Mrs Hyunju Park) has granted permission to Springer 
Nature Limited to publish the images of the mice in Fig. 3 of the manuscript entitled “ENOblock inhibits the 
pathology of diet-induced obesity” by Cho, et al., under a CC BY open access license.
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Figure 4. Effect of ENOblock treatment on glucose homeostasis, insulin resistance and gluconeogenesis in diet-
induced obese mice. (A,B) Glucose tolerance test (GTT) and area under the curve (AUC) for HFD mice treated 
with ENOblock or rosiglitazone for 4 weeks. (C,D) Insulin tolerance test (ITT) and AUC for the treated HFD 
mice after 5 weeks of ENOblock or rosiglitazone treatment. (E,F) Insulin serum level and determination of insulin 
resistance level in HFD mice after 8 weeks of ENOblock or rosiglitazone treatment. (G,H) Pyruvate tolerance 
test (PTT) after 7 weeks of drug treatment to determine gluconeogenesis level. SFD = mice fed standard chow; 
HFD = high fat diet-fed mice; HFD-ENO = ENOblock treated HFD mice; HFD-Rosi = rosiglitazone treated 
HFD mice. n = 6; ns: not significantly different. *, ** or ***: significantly different from the corresponding 
‘SFD-Normal’ or ‘SFD-Control’ (Standard Fat Diet-none-treated normal healthy mouse group) respectively with 
p < 0.05, p < 0.01 or p < 0.001; ## or ###: significantly different from the corresponding ‘HFD-none’ or ‘HFD-
Control’ (HFD-non-treated control mouse group) sample with p < 0.01 or p < 0.001; ж, жж or жжж: significantly 
different from the corresponding ‘HFD-Rosi’ sample respectively with p < 0.05, p < 0.01 or p < 0.001.
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Figure 5. Consequence of ENOblock treatment on liver pathology in obese mice. (A) Representative photographs 
of the liver in HFD mice treated with ENOblock or rosiglitazone. Age-match SFD liver is included for comparison. 
(B) Liver weight in the treated mice. n = 6. (C) Serum levels of the liver enzyme alanine aminotransferase (ALT). 
n = 6. (D) Oil red O staining to visualize lipid accumulation in liver tissue. (E) Quantification of lipid accumulation. 
n = 30 randomly selected lipid droplets in 5 randomly captured microscope images from 5 mouse livers/treatment 
group. (F) H&E staining to visualize microsteatosis. (G) Quantification of microsteatosis. n = 10 different regions 
of 5 mouse livers per treatment group. (H) Masson’s Trichrome staining to indicate fibrosis (blue color) in the liver 
tissue. (I) Quantification of fibrosis. n = 8 to 10 randomly captured microscope images from sections, prepared from 
5 mouse livers per treatment group. (J) α-SMA immunostaining to detect hepatic stellate cells. (K) Quantification 
of hepatic stellate cells. n = 10 randomly captured microscope images of cryo-sections from 5 mouse livers per 
treatment group. (L) qPCR analysis of α-Sma expression. n = 5 For (D), (F), (H) and (J); Scale bar = 100 µm. ns: not 
significantly different. *, ** or ***: significantly different from the corresponding ‘SFD-Normal’ or ‘SFD-Control’ 
(Standard Fat Diet-none-treated normal healthy mouse group) respectively with p < 0.05, p < 0.01 or p < 0.001; ## or 
###: significantly different from the corresponding ‘HFD-none’ or ‘HFD-Control’ (HFD-non-treated control mouse 
group) sample with p < 0.01 or p < 0.001; ж, жж or жжж: significantly different from the corresponding ‘HFD-Rosi’ 
sample respectively with p < 0.05, p < 0.01 or p < 0.001.
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ENOblock treatment prevents inflammation and induces suppressors of lipid homeostasis and 
gluconeogenesis in the liver of obese mice. HFD-induced liver steatosis can progress to chronic inflam-
mation and cirrhosis45. Assessment of liver inflammatory markers indicated that HFD increased expression of 
interleukin-6 (Il-6) and tumor necrosis factor-alpha (Tnf-α). ENOblock or rosiglitazone treatment reduced the 
expression of Tnf-α and Il-6, which were normalized compared to SFD mice (Fig. 6A,B). S100 calcium-binding 
protein A9 (S100a9) regulates myeloid cell function and is a biomarker for non-alcoholic steatohepatitis46. S100a9 
expression was increased in HFD compared to SFD mice. Rosiglitazone treatment further increased S100a9 
expression in the HFD mice, whereas ENOblock treatment had no effect (Fig. 6C).
Sterol regulatory element-binding proteins (Srebp-1a and Srebp-1c) are key regulators of lipid synthesis47. 
Srebp-1a and Srebp-1c expression was upregulated in the liver of HFD mice compared to SFD mice. ENOblock 
treatment inhibited Srebp-1a and Srebp-1c expression (Fig. 6D). Rosiglitazone treatment also inhibited Srebp-1a 
and Srebp-1c expression. Insig-1 and Insig-2 proteins block the maturation of Srebp-1a and Srebp-1c in the 
Golgi47, and are in turn regulated by autocrine motility factor receptor, isoform 2 (Amfr, also known as Gp-78)48. 
ENOblock treatment did not significantly affect the expression of Amfr and Insig-1, but did inhibit Insig-2 expres-
sion (Fig. 6E). In addition, expression of the liver X receptor (LXR) target genes, Scap and Abcg5, were either unaf-
fected or inhibited by ENOblock treatment, respectively (Fig. 6F). The onset of prediabetes in obesity is associated 
with dysregulated gluconeogenesis, which is positively regulated by phosphoenolpyruvate carboxykinase (Pck)49. 
HFD mice showed elevated expression of Pck-1 and Pck-2 compared to SFD mice. ENOblock or rosiglitazone 
treatment reduced Pck-1 and Pck-2 expression in the HFD mice (Fig. 6G).
The mechanism by which ENOblock inhibits steatosis in HFD mice was assessed by measuring the expression 
of key regulators of adipogenesis: Adipoq, Ap2, Ppar-γ, Retn and Cebpa33. HFD mice showed upregulated expres-
sion of all 5 adipogenic genes compared to SFD mice. ENOblock treatment reduced the expression of all 5 genes 
to the level observed in SFD mice (Fig. 6H). Rosiglitazone treatment reduced the expression of Ppar-γ, Retn and 
Cebpa in HFD mice, but did not significantly reduce the expression of Adipoq and Ap2.
ENOblock prevents mitochondrial loss and reduces inflammatory marker expression in the 
hippocampus of obese mice. Obesity has been linked with hippocampal dysfunction and memory 
impairment, which is thought to result from HFD-induced inflammatory responses in the hippocampus50,51. 
After 8 weeks, HFD mice showed increased expression of the hippocampal inflammatory markers toll-like recep-
tor (Tlr4), Il-6, Tnf-α and CD11c compared to SFD mice. ENOblock treatment reduced the expression of these 
inflammatory markers in HFD mice to the level observed in SFD mice (for Tnf-α and Cd11c) or lower than 
SFD mice (for Tlr4 and Il-6) (Fig. 7A). Rosiglitazone treatment also reduced hippocampal inflammatory marker 
expression. Neuronal pentraxin-2 (Nptx2) regulates synaptic plasticity and is a pro-inflammatory biomarker of 
non-apoptotic neuronal cell death52. Nptx2 expression was upregulated in the HFD mice compared to SFD mice. 
ENOblock treatment reduced Nptx2 expression in the HFD mice to the level observed in SFD mice (Fig. 7A). 
Rosiglitazone also reduced Nptx2 expression in the HFD mice.
HFD is known to reduce mitochondrial mass in various cell types, which can produce changes in brain ener-
getics and infrastructure53,54. Transcription factor A of the mitochondria (Tfam) is positively linked to the reg-
ulation of mitochondrial genome copy number55. Tfam expression was reduced in the hippocampus of HFD 
mice compared to SFD mice. ENOblock treatment increased Tfam expression to the levels observed in SFD mice 
(Fig. 7B). Rosiglitazone treatment also increased Tfam expression in HFD mice. The transcription factor cAMP 
response element-binding protein (Creb) is sensitive to alterations in the energy status of neuronal cells56. Creb 
expression was increased in the HFD mice compared to SFD mice. ENOblock, but not rosiglitazone, treatment 
reduced Creb expression in HFD mice (Fig. 7B). Transcription factor nuclear respiratory factors (Nrf-1 and Nrf-
2) regulates neurite outgrowth and mitochondrial biogenesis57,58. Nrf-1 expression was reduced in HFD mice 
and ENOblock treatment significantly increased Nrf-1 expression (Fig. 7B). In contrast, Nrf-2 expression was 
elevated in HFD mice and reduced by ENOblock treatment (Fig. 7B). Rosiglitazone treatment did not affect Nrf-
1 expression but, similar to ENOblock treatment, reduced the expression of Nrf-2. The negative effects of HFD 
on hippocampal bioenergetics was indicated by a reduction in mtDNA content. ENOblock treatment prevented 
the reduction of mtDNA content (Fig. 7C). Rosiglitazone treatment also improved mtDNA content compared to 
HFD mice, but with less significance than ENOblock treatment (p < 0.05 compared with p < 0.01, respectively). 
Nissl staining of hippocampal neurons did not show histological differences in neural survival in SFD, HFD or 
ENOblock-treated HFD mice (Fig. 7D). Rosiglitazone-treated mice showed disrupted Nissl staining in the CA1 
region of the hippocampus.
ENOblock lowers serum lipids and adiposity in diet-induced obese mice. HFD mice showed ele-
vated serum levels of triglyceride, HDL cholesterol and LDL cholesterol after 8 weeks (Fig. 8A–C). HFD mice 
treated with rosiglitazone showed a further increase in serum triglyceride, reduced HDL cholesterol and no sig-
nificant change in LDL cholesterol level. HFD mice treated with ENOblock showed reduced serum triglyceride 
and LDL cholesterol compared to untreated HFD mice. Serum LDL cholesterol in ENOblock-treated HFD mice 
reached the same range as SFD mice.
Representative photographs of gonadal WAT are shown in Fig. 8D. ENOblock treatment in HFD mice reduced 
gonadal tissue weight, whereas rosiglitazone treatment had no significant effect (Fig. 8E). Increases in adipocyte 
size in the gonadal WAT of HFD mice was prevented by ENOblock treatment, which was more effective than 
rosiglitazone at reducing adipocyte size (Fig. 8F,G). Modulators of the thermogenesis program in BAT and obesity 
have been shown to induce beige-like adipogenesis in WAT33. H&E staining revealed the infiltration of beige-like 
adipocytes in the gonadal WAT of ENOblock-treated HFD mice (Fig. 8I). ENOblock and rosiglitazone treatment 
also down-regulated expression of the inflammatory markers TNF-α and Cd11c, but not Mcp-1 in gonadal WAT 
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(Fig. 8I). Expression of the master mediator of adipogenesis, Pparγ59 was down-regulated in gonadal WAT by 
ENOblock treatment (Fig. 8I). Rosiglitazone treatment produced a smaller inhibition in Pparγ in HFD gonadal 
WAT compared to ENOblock.
Figure 6. Effect of ENOblock on indicators of liver inflammation, lipogenesis and gluconeogenesis. (A,B) 
ELISA analysis of the inflammatory markers TNF-α and IL-6 in the liver of SFD, HFD and HFD mice treated 
with ENOblock or rosiglitazone for 8 weeks. n = 5 (C) Expression of the inflammatory markers Il-6, Tnf-α 
and s100a9 in liver tissue of the treated mice. (D) qPCR analysis of the expression of the lipid homeostasis 
regulators, Srebp-1a and Srebp-1c. (E) qPCR analysis of the expression of the regulators of Srebp-1a and Srebp-1c 
processing, Amfr, Insig-1 and Insig-2. (F) Expression of the LXR target genes, Scap and Abcg5. (G) Expression 
of the gluconeogenesis regulators, Pck-1 and Pck-2. (F) Expression of the adipogenesis markers Adipoq, Ap2, 
Ppar-γ, Retn and Cebpa. SFD = mice fed standard chow; HFD = high fat diet-fed mice; HFD-ENO = ENOblock 
treated HFD mice; HFD-Rosi = rosiglitazone treated HFD mice. For (C–F) n = 5. ns: not significantly different. 
*, ** or ***: significantly different from the corresponding ‘SFD-Normal’ or ‘SFD-Control’ (Standard Fat 
Diet-none-treated normal healthy mouse group) respectively with p < 0.05, p < 0.01 or p < 0.001; ## or ###: 
significantly different from the corresponding ‘HFD-none’ or ‘HFD-Control’ (HFD-non-treated control mouse 
group) sample with p < 0.01 or p < 0.001; ж, жж or жжж: significantly different from the corresponding ‘HFD-
Rosi’ sample respectively with p < 0.05, p < 0.01 or p < 0.001.
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Representative photographs of interscapular BAT are shown in Fig. 8J. HFD mice treated with ENOblock or 
rosiglitazone showed increased interscapular BAT weight compared to HFD or SFD mice (Fig. 8K). The effect 
of ENOblock on BAT weight was greater than that observed in the rosiglitazone-treated mice. H&E staining 
of interscapular BAT indicated reduced adipocyte size in ENOblock treated HFD mice compared to HFD, 
rosiglitazone-treated HFD and SFD mice (Fig. 8L). The markers of inflammation Tnf-α, Cd11c and Mcp-1, and 
the master regulator of adipogenesis Pparγ all showed down-regulated expression in HFD BAT after ENOblock 
or rosiglitazone treatment (Supplementary Fig. 6). Masson’s Trichrome staining demonstrated that ENOblock or 
rosiglitazone treatment inhibited the development of fibrosis in HFD BAT (Supplementary Fig. 7).
ENOblock prevents the symptoms of pre-diabetes in obese mice at a comparable level to met-
formin. Obesity is associated with the development of prediabetes/insulin resistance, which also occurs in the 
diet-induced obesity mouse model60. To assess the potential effectiveness of ENOblock for preventing prediabetes 
in obesity, HFD mice were treated with ENOblock or metformin (GlucophageTM), which is a first line treatment 
for diabetes in obese patients61,62. The treatment schedule for ENOblock and metformin in HFD mice is shown 
in Fig. 9A. After 8 weeks, metformin and ENOblock treated HFD mice showed decreased quantities of visceral 
fat (Fig. 9B). During the course of drug treatment, both ENOblock and metformin reduced body weight. After 
7 weeks, the ENOblock treated mice were significantly lighter than the mice treated with metformin (Fig. 9C). 
Fasted blood glucose was lowered in both metformin and ENOblock treated HFD mice, with ENOblock treated 
mice showing lower blood glucose levels than metformin treated mice at 6 weeks of drug treatment (Fig. 9D). A 
glucose tolerance test (at 4 weeks treatment), insulin tolerance test (at 5 weeks) and pyruvate tolerance test (at 7 
weeks) indicated that ENOblock and metformin produce comparable improvements in insulin resistance/sensi-
tivity and gluconeogenesis level, which all fell within the range observed in SFD mice (Fig. 9E–J).
ENOblock treatment in obese mice reduced hyperinsulinemia and increased the population 
of anti-inflammatory M2 macrophages in the adipose tissue. The HFD mice also displayed hyper-
insulinemia and elevated HOMA-IR, which was decreased by ENOblock or metformin treatment (Fig. 10A,B). 
Figure 7. Hippocampus expression of inflammatory markers and sensors of energy status, mitochondrial 
content and neuronal histology in obese mice after ENOblock treatment. (A) Expression of the inflammatory 
markers Il-6, Tnf-α, Cd11c, Tlr-4 and Nptx2 in the hippocampus. (B) Expression of the energy status sensor, 
Creb, and the regulators of mitochondrial biogenesis, Tfam, Pgc1α, Pgc1β, Nrf1, and Nrf2. (C) Mitochondrial 
DNA content in the hippocampus. (D) Nissl staining of neurons in the CA1, CA2 and CA3 regions of the 
hippocampus. Note the disorganized neuronal structures in the CA1 region of rosiglitazone treated mice. Scale 
bar = 100 µm. SFD = mice fed standard chow; HFD = high fat diet-fed mice; HFD-ENO = ENOblock treated 
HFD mice; HFD-Rosi = rosiglitazone treated HFD mice. For (A–D) n = 5 ns: not significantly different. *, ** 
or ***: significantly different from the corresponding ‘SFD-Normal’ or ‘SFD-Control’ (Standard Fat Diet-none-
treated normal healthy mouse group) respectively with p < 0.05, p < 0.01 or p < 0.001; ## or ###: significantly 
different from the corresponding ‘HFD-none’ or ‘HFD-Control’ (HFD-non-treated control mouse group) 
sample with p < 0.01 or p < 0.001; ж, жж or жжж: significantly different from the corresponding ‘HFD-Rosi’ 
sample respectively with p < 0.05, p < 0.01 or p < 0.001.
www.nature.com/scientificreports/
1 2Scientific REPORTS |           (2019) 9:493  | DOI:10.1038/s41598-018-36715-3
Figure 8. Effect of ENOblock treatment on adiposity in diet-induced obese mice. (A–C) Serum levels of 
triglyceride, HDL and LDL cholesterol in SFD, HFD, and HFD mice after 8 weeks’ treatment with ENOblock 
or rosiglitazone. n = 5–6. (D) Representative photographs of the dissected gonadal WAT. (E) Gonadal WAT 
weight. n = 6. (F) H&E stained gonadal adipose tissue to visualize adipocyte size distribution. (G) Variation in 
adipocyte width in the treated mice. n = 5 mice per treatment group were stained and 100 randomly selected 
adipocytes measured. (H) Indication of regions of beige-like adipocytes in H&E stained gonadal WAT from 
ENOblock treated HFD mice (indicated using white arrows). (I) qPCR analysis of the inflammatory markers 
Tnf-α, Cd11c and Mcp-1, and the master adipogenesis regulator, Pparg in gonadal WAT. Expression is compared 
using a log scale. n = 5. (J) Representative photographs of interscapular BAT. (K) Interscapular BAT weight. 
n = 6. (L) H&E stained interscapular BAT to visualize adipocyte size distribution. SFD = mice fed standard 
chow; HFD = high fat diet-fed mice; HFD-ENO = ENOblock treated HFD mice; HFD-Rosi = rosiglitazone 
treated HFD mice. For (F), (H) and (L); Scale bar = 100 µm. ns: not significantly different. *, ** or ***: 
significantly different from the corresponding ‘SFD-Normal’ or ‘SFD-Control’ (Standard Fat Diet-none-treated 
normal healthy mouse group) respectively with p < 0.05, p < 0.01 or p < 0.001; ## or ###: significantly different 
from the corresponding ‘HFD-none’ or ‘HFD-Control’ (HFD-non-treated control mouse group) sample 
with p < 0.01 or p < 0.001; ж, жж or жжж: significantly different from the corresponding ‘HFD-Rosi’ sample 
respectively with p < 0.05, p < 0.01 or p < 0.001.
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Figure 9. Comparison of ENOblock and metformin on parameters of obesity and pre-diabetes in diet-
induced obese mice. (A) Schematic of the ENOblock and metformin treatment protocol in HFD mice. (B) 
Representative photographs of dissected mice to show visceral fat tissues (white arrows). (C) Body weight in 
the treated mice during drug treatment. (D) Fasted blood glucose at 4 and 6 weeks dug treatment. (E,F) GTT 
and area under the curve after 4 weeks drug treatment. (G,H) ITT and area under the curve after 5 weeks drug 
treatment. (I,J) PTT and area under the curve after 7 weeks drug treatment. SFD = mice fed standard chow; 
HFD = high fat diet-fed mice; HFD-ENO = ENOblock treated HFD mice; HFD-Metf = metformin treated 
HFD mice. n = 6–10; ns: not significantly different. *, ** or ***: significantly different from the corresponding 
‘SFD-Normal’ or ‘SFD-Control’ (Standard Fat Diet-none-treated normal healthy mouse group) respectively 
with p < 0.05, p < 0.01 or p < 0.001; ## or ###: significantly different from the corresponding ‘HFD-none’ or 
‘HFD-Control’ (HFD-none-treated control mouse group) sample with p < 0.01 or p < 0.001; ж, жж or жжж: 
significantly different from the corresponding ‘HFD-Metf ’ sample respectively with p < 0.05, p < 0.01 or 
p < 0.001.
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After 8 weeks’ treatment, ENOblock treatment produced a significantly greater reduction in hyperinsulinemia 
and HOMA-IR compared to metformin. Representative photographs of dissected gonadal WAT are shown in 
Fig. 10C. ENOblock and metformin treatment reduced gonadal WAT weight, with ENOblock producing a larger 
effect than metformin (Fig. 10D). Obesity is associated with adipose tissue inflammation, which is characterized 
by decreased numbers of anti-inflammatory ‘M2’ type macrophages63,64. Flow cytometry analysis of the expres-
sion of the pan-macrophage marker CD68 (macrosialin) and the M2 macrophage marker CD206 (mannose 
receptor) in WAT-derived inflammatory cells confirmed a reduction in M2 macrophage numbers in HFD mice 
compared to SFD mice. ENOblock treatment increased the proportion of M2 macrophages in the adipose tissue 
Figure 10. Effect of ENOblock or metformin treatment on HOM-IR and WAT inflammatory status in diet-
induced obese mice. (A,B) Insulin serum level and insulin resistance in ENOblock or metformin treated HFD 
mice over 8 weeks of treatment. n = 6–10. (C) Representative photographs of dissected gonadal WAT. (D) 
Gonadal WAT weight in the treated mice. n = 6–10. (E) Representative flow cytometry plots of WAT-derived 
inflammatory cells stained with antibodies for the pan-macrophage marker, CD68 (macrosialin) and the M2 
anti-inflammatory macrophage marker, CD206 (mannose receptor. (F) Quantification of the percentage of M2 
type macrophages in the inflammatory population of WAT from the treated mice. n = 6. ns: not significantly 
different. *, ** or ***: significantly different from the corresponding ‘SFD-Normal’ or ‘SFD-Control’ (Standard 
Fat Diet-none-treated normal healthy mouse group) respectively with p < 0.05, p < 0.01 or p < 0.001; ## or ###: 
significantly different from the corresponding ‘HFD-none’ or ‘HFD-Control’ (HFD-none-treated control mouse 
group) sample with p < 0.01 or p < 0.001; ж, жж or жжж: significantly different from the corresponding ‘HFD-
Metf ’ sample respectively with p < 0.05, p < 0.01 or p < 0.001.
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of HFD mice. Metformin treatment produced a variable response in the HFD mice and, overall, the proportion of 
M2 macrophages was not significantly changed compared to untreated HFD mice (Fig. 10E,F).
To further characterize the anti-obesity potential of ENOblock treatment, a short-term study was carried out 
in normal mice fed a HFD, to measure fecal fat content and cumulative food intake. The effect of ENOblock was 
compared with the clinically approved anti-obesity drug, orlistat26. It was observed that ENOblock or orlistat 
treatment reduced body weight gain (Supplementary Fig. 8A). Orlistat or ENOblock treatment also increased 
fecal fat content, although the effect of orlistat was much greater than ENOblock (Supplementary Fig. 8B). 
ENOblock, but not orlistat, treatment also reduced cumulative food intake in the treated mice after 20 days 
(Supplementary Fig. 8C).
Discussion
The rising rates of obesity have become a major health concern. Developing novel therapeutics and new drug tar-
gets to treat obesity is a research priority. In this study, we investigated a novel small molecule enolase modulator, 
ENOblock, as a candidate drug and enolase-mediated transcriptional repression as a potential target for treating 
obesity and obesity-related complications.
Our study utilized the diet-induced model of obesity, in which mice are fed a highly palatable diet containing 
a high level of fats and sugar. Although this model is harder to establish than genetic models of obesity, it is con-
sidered superior for testing candidate therapeutics because it more closely resembles obesity in humans, which 
results from a combination of polygenic and environmental influences60.
The effect of ENOblock on adipogenesis was found to be dependent on the differentiation status of preadi-
pocytes in vitro (Fig. 1). Key gene regulators of adipogenesis were found to be expressed in preadipocytes using 
qPCR. However, ENOblock treatment had a relatively minor effect on adipogenic gene expression in the pread-
ipocytes (2 out 7 genes analyzed). In the presence of adipogenic factors that promote differentiation, ENOblock 
repressed all 7 adipogenic genes, irrespective of the treatment timing, i.e. before or after adding the adipogenic 
factors (Figs 1B and 2B). This contrasts with epigenetic factors that control adipogenesis, such as lysine-specific 
demethylase 1, which are only effective at the initiation of the adipogenic differentiation33. The ability of 
ENOblock to suppress adipogenesis was similar to the positive control compound, rapamycin, which also inhib-
ited the expression of all 7 adipogenic genes (Fig. 2A,H,I). Moreover, our in vitro results indicate that ENOblock 
may promote mitochondrial membrane uncoupling and thermogenesis in preadipocytes via upregulation of Ucp-
1, or Ucp-3, which was detected in preadiocytes and differentiating adipocytes, respectively (Fig. 1D,H). It has 
previously been reported that thermogenesis induction is also linked to the induction of regulators oxidative 
metabolism, such as Nrf1, Cpt1b and Cox8b33. Our results indicate the ENOblock treatment does not upreg-
ulate these three oxidative markers under non-adipogenic or adipogenic conditions (Figs 1C,G and 2C) or in 
brown preadipocytes (Supplementary Fig. 3C). However, the upregulation of uncoupling proteins by ENOblock 
appeared to be sufficient to induce mitochondrial inner membrane depolarization (Fig. 2E,F). Moreover, our pos-
itive control compound, forskolin, also induced membrane depolarization without upregulating Nrf1, Cpt1b and 
Cox8b (Fig. 2C). It should be noted that NaF, an inhibitor of enolase enzyme activity but not nuclear translocation, 
did not induce mitochondrial membrane depolarization or upregulate uncoupling proteins (Fig. 2D–F), impli-
cating ENOblock-mediated targeting of enolase secondary functions as a mechanism producing depolarization.
In obese HFD mice, ENOblock reduced weight gain, and normalized both body weight and temperature to 
the range observed in SFD mice (Fig. 3C–E,G). However, it should be noted that dual-energy x-ray absorptiome-
try (DEXA) analysis would have been an ideal method for assessing fat re-distribution in ENOblock treated mice, 
and is essential for further assessment of the anti-obesity effects of this compound in animal models. These effects 
on body weight were achieved without influencing food intake, suggesting that the anti-obesity mechanisms of 
ENOblock as the inhibition of adipogenesis and enhancement of mitochondrial membrane depolarization in 
adipose tissues, rather than appetite suppression. ENOblock also suppressed the symptoms of pre-diabetes to a 
level comparable with the anti-diabetic drug, rosiglitazone (Figs 3H and 4A–H), although rosiglitazone did not 
produce anti-obesity effects in this model system.
In HFD mice liver, ENOblock reduced lipid accumulation, the development of steatosis and fibrosis, and the 
activation of stellate cells (Fig. 5D–I). In contrast, rosiglitazone did not reduce these pathological parameters. One 
potential explanation for these differences between the two drugs is the inability of rosiglitazone to down-regulate 
Ap2 expression and the strong induction of S100a9 expression observed in HFD mice (Fig. 6C,H). Ap2 is a major 
inducer of adipogenesis and abundantly expressed in adipocytes, representing as much as 1–3% of the soluble 
protein, and S100a9 regulates fibrosis because it stimulates myeloid inflammatory cells via toll-like receptor 4 and 
NF-κ-B46,65. Obesity is an inflammatory disease66,67 and ENOblock treatment reduced expression of the inflam-
matory markers Il-6 and Tnf-α (Fig. 6C). Due to the mechanistic connection between obesity, inflammation and 
fibrosis, ENOblock can reduce fibrosis by targeting inflammatory responses in the HFD liver.
ENOblock treatment repressed the expression of Srebp-1a and Srebp-1c, which are major regulates of lipid 
homeostasis40, in the liver of HFD mice (Fig. 6D), providing a mechanistic explanation for the reduced adiposity 
observed in the ENOblock-treated mice. Reduced gene expression of Srebp-1a and Srebp-1c appears to be the 
main mechanism by which ENOblock represses these factors, because ENOblock treatment did not enhance 
the expression of Amfr, Insig-1 and Insig-2, which would decrease the protein activity of Srebp-1a and Srebp-1c 
(Fig. 6E). This contrasts with known regulators of Srebp, such as betulin, a small molecule component of birch 
(Betula) tree bark, which block Srebp protein cleavage and activation40. ENOblock treatment disrupted Srebp 
expression without increasing expression of the LXR target genes, Scap and Abcg5, which may cause hepatic 
steatosis and hypertriglyceridemia when Srebp expression is inhibited by pharmacological ligands40 (Fig. 6F). 
However, it should be noted that while enolase siRNA treatment reduced enolase expression at both concentra-
tions tested (40 and 60 pmol), Srebp-1a, -1c, and -2 expression was only reduced at the 40 pmol concentration 
(Supplementary Fig. 2A,B). One possible explanation for this finding is that the different siRNA concentrations 
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produced different effects on the cytoplasmic and nuclear distribution of enolase, and this should be addressed in 
subsequent studies of enolase-mediated regulation of Srebp-1a, -1c, and -2 expression.
Obesity has been linked with impaired memory formation and hippocampal dysfunction51. All five markers of 
obesity-related inflammation in the hippocampus (Il-6, Tnf-α, Cd11c, Tlr4 and Nptx251,52) were down-regulated 
by ENOblock treatment (Fig. 6A). The expression of memory-associated genes in the hippocampus, such as 
Creb and Tfam, are tightly regulated to ensure correct establishment of long-term synaptic connections between 
neurons during memory formation50,51. In the hippocampus, Creb is an important sensor of energy status and 
functions in memory formation56,68. Obese mice in our study showed increased expression of hippocampal Creb, 
which has also been demonstrated previously54 and is known to interfere with memory formation69. ENOblock 
treatment reduced hippocampal Creb expression in obese mice (Fig. 7B). ENOblock treatment also produced a 
recovery in Tfam expression in HFD mice and increased hippocampal mitochondrial DNA content to the range 
observed in lean SFD mice (Fig. 7B,C). Although Nrf-1 and Nrf-2 expression showed opposite changes in obese 
mice (Fig. 7B), Nrf-1 is thought to be the dominant factor determining Tfam promoter activity and mitochon-
drial biogenesis58. Although rosiglitazone treatment produced beneficial effects on inflammatory gene expression 
and mitochondrial DNA content, this drug appeared to produce neurotoxicity in the hippocampus, as indicated 
by a disrupted pattern of Nissl staining in the CA1 region (Fig. 7D). To our knowledge, this is the first demon-
stration that rosiglitazone can produce toxicity in the hippocampus. Overall, this data indicates that ENOblock 
treatment has the potential to correct the initiation of hippocampus impairment caused by diet-induced obesity. 
Further functional analyses, such as the Morris water maze, anxiety and anhedonia tests, would be needed to 
support this conclusion. We do not believe that the effects on gene expression in the brain are only restricted to 
the hippocampus. For example, the effect on ENOblock on suppressing the expression of inflammation-related 
genes was observed in the hippocampus, adipose and liver tissues. Therefore, other regions of the brain may show 
similar effects on gene expression.
The effect of ENOblock to down-regulate adipogenic gene expression in vitro, and Srebp-1a and Srebp-1c in 
liver tissue in vivo, was reflected in the marked reduction in the adiposity of ENOblock treated HFD mice (Fig. 8). 
Serum lipids, WAT mass and adipocyte size were significantly reduced (Fig. 8A–G). One goal in anti-obesity 
research is to develop drugs that mimic the normal cold exposure response by the central nervous system to pro-
duce ‘browning’ of white adipose tissue70. H&E staining of WAT indicated the presence of beige-like adipocytes 
in ENOblock treated mice, which was suggested by the mitochondrial depolarization observed in preadipocytes 
in vitro (Figs 2E,F and 8H). Compared to HFD mice, ENOblock treatment significantly upregulated Ucp-3 in 
WAT and BAT (Supplementary Figs 5 and 6, respectively), which was also observed in differentiating preadipo-
cytes in vitro (Fig. 2H). Ucp-3 overexpression has been shown to produce fat-specific weight loss71. Therefore, we 
speculate that Ucp-3 up-regulation in by ENOblock also contributes to reduced WAT mass and the appearance 
of beige-like adipocytes. In BAT, ENOblock treatment produced an increase in weight without increasing tissue 
size (Fig. 8J,K). This may be due to reduced lipid content and increased connective tissue in BAT after ENOblock 
treatment (Fig. 8L), which has been shown to increase BAT density72. Inflammatory regulators Il-6 and Tnf-α 
were down-regulated by ENOblock in both WAT and BAT (Fig. 8I and Supplementary Fig. 6), providing a mech-
anistic explanation for the reduced BAT fibrosis in ENOblock treated mice (Supplementary Fig. 7).
We did not observe hepatotoxicity in the ENOblock treated group, as indicated by a significant reduction in 
alanine aminotransferase levels compared to high fat diet (HFD) mice, which fell to the range observed in SFD 
mice (Fig. 5C). In our previous study using a genetic model of type 2 diabetes (the db/db mouse), we assessed 
potential effects on genes linked to cardiotoxicity genes (Kcnk1, Asah2, B4glant, MMP-3), and reported no adverse 
effects after ENOblock treatment7,73. Although we observed no acute toxicity in the diet-induced obese mice after 
ENOblock treatment, we acknowledge that in-depth toxicological analysis should be an important component 
of future studies of ENOblock in animal models. For example, the weight loss produced by ENOblock treatment 
may be due to nausea or other non-specific effects, which would influence metabolism and decrease body weight.
In light of our finding that ENOblock improved both adiposity and the symptoms of obesity-related pre-
diabetes, this drug was compared with metformin; the most commonly prescribed drug for this condition in 
patients29–31. Both drugs produced broadly similar effects on pre diabetic symptoms, although ITT (AUC), fasted 
blood glucose at 6 weeks and HOMA-IR were lower with ENOblock treatment (Figs 9D,F and 10A). Metformin 
treatment in patients has been observed to produce weight loss as a side effect74. In this diet-induced obesity 
model, ENOblock produced greater effects than metformin on whole body and WAT weight (Figs 9B,C and 
10C,D). We also confirmed that anti-inflammation effect of this drug by demonstrating reduced inflammatory 
status in HFD WAT tissue (Fig. 10E,F). These results support the potential of ENOblock for development as an 
anti-obesity therapeutic.
It was previously shown that modulation of another glycolysis enzyme, glucokinase (hexokinase 4), by the 
compound PF-04991532 reduced hyperglycemia without causing hepatic steatosis in non-obese diabetic rats75. 
PF-04991532 enhances glucokinase activity and glycolysis, whereas ENOblock has been shown to not affect76 
or reduce enolase enzyme activity7,8,12. This supports the modulation of non-enzymatic enolase transcriptional 
repression by ENOblock as the more likely mechanism for producing anti-obesity effects, because reduced eno-
lase enzyme activity should inhibit glycolysis, which would decrease cellular glucose uptake and promote hyper-
glycemia. Moreover, PF-04991532 also increased plasma triglycerides, whereas ENOblock significantly reduced 
serum triglyceride and LDL cholesterol in our obesity model (Fig. 8A–C).
Enolase is a highly conserved, ancient enzyme that is widely expressed in all cells capable of glycolysis and 
fermentation. A number of glycolytic enzymes have been shown to moonlight in the cell nucleus and elucidation 
of the roles of these enzymes in the nucleus during pathological states has become a prominent area of research 
(reviewed in9,77,78). Recently, there is increased appreciation of the link between glycolytic enzyme nuclear trans-
location and metabolic status of cells, which regulates the cell response to environmental factors such as nutrient 
availability9. For example, pyruvate kinase translocates to the nucleus and induces the expression of glycolysis 
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enzymes via binding to the master transcription factor, hypoxia-inducible factor-1α (HIF-1α)9. Gluconeogenesis 
can be considered the ‘reverse’ pathway of glycolysis. Therefore, the induction of glycolysis gene expression in 
cells would suppress gluconeogenesis. Our study and a recent report also shows that enolase nuclear translo-
cation via ENOblock treatment also represses gluconeogenesis and down-regulates the master regulator, Pck1 
(Figs 4E–G and 6G). A greater understanding of the link between enolase nuclear translocation and peripheral 
oxidative capacity will be needed to fully interpret the utility of this mechanism for treating metabolic disorders 
and obesity.
In summary, obesity is a disease that has become a major global medical and economic burden. Current phar-
macological approaches to treat obesity have only achieved limited success and produced side effects79. In this 
study, the compound ENOblock, a modulator of enolase moonlighting as a transcriptional repressor, ameliorated 
hyperglycemia and reduced adiposity in a diet-induced model of weight gain that closely resembles the patho-
genesis of human obesity. ENOblock treatment inhibited gluconeogenesis, adiposity and obesity-related inflam-
mation via concomitant repression of the regulatory genes Pck-1, Srebp-1a and Srebp-1c, and Tnf-a and Il-6. These 
genetic alterations also produced mitochondrial uncoupling and the recovery of down-regulated Ucp-3 in WAT. 
A schematic of the major findings in this study is presented in Fig. 11. Overall, these results suggest ENOblock 
as a candidate therapeutic and enolase sub-cellular localization (moonlighting) as a target for anti-obesity drug 
development.
Materials and Methods
Reagents and Antibodies. ENOblock(N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-4-[[4-[(cyclohexylme-
thyl)amino]-6-[[(4-fluorophenyl)methyl]amino]-1,3,5-triazin-2-yl]amino]-benzeneacetamide hydrochloride) 
was designed and synthesized by Professor Young-Tae Chang, Pohang University of Science and Technology, 
Republic of Korea and synthesized Professor Jin Hee Ahn, Gwangju Institute of Science and Technology, Republic 
of Korea, in accordance with the published protocol6. Dexamethasone, forskolin, rapamycin and rosiglitazone 
were purchased from Santa Cruz Biotechnology (CA, USA). Metformin (1,1-dimethylbiguanide hydrochlo-
ride), orlistat, OSMI-1, 3-isobutyl-1-methylxanthine (IBMX), sodium fluoride (NaF), oil red O and an anti-
body for α–smooth muscle actin (catalogue number A5228) were purchased from Sigma-Aldrich (MO, USA). 
Tetramethylrhodamine, ethyl ester, perchlorate (TMRE) was purchased from Thermo Fisher Scientific (MA, 
USA).
Cell Culture. 3T3-L1 murine preadipocytes were obtained from the Korean Cell Line Bank (Seoul National 
University, Republic of Korea) and cultured in DMEM supplemented with 10% calf serum, 50 units mL−1 peni-
cillin and 50 µg mL−1 streptomycin (PenStrep). 3T3-L1 cells were induced to differentiate into adipocytes follows: 
48 h post-confluent cells (designated day 0) were cultured in DMEM supplemented 10% FBS, 0.5 mM IBMX, 
2 µg/ml dexamethasone, 1 µg/mL insulin and PenStrep for 2 days. Thereafter, the cells were incubated with fresh 
DMEM supplemented with 10% FBS and 1 µg/mL insulin. Hep G2 human hepatocytes were obtained from the 
Korean Cell Line Bank and cultured in DMEM supplemented 10% FBS and 1% PenStrep.
Isolation of primary preadipocytes. 8 week old male C57BL/6 J mice were purchased from Damool 
Science, Republic of Korea. The protocol to isolate primary preadipocytes was based on a previously published 
methodology33. In brief, mice were sacrificed and entire white gonadal tissue or interscapular brown adipose 
tissue were dissected and homogenized in 1 mL DPBS containing 0.5% BSA. Tissues were then treated with 0.8 U/
mL collagenase and 2.7 U/mL dispase in 3 mL digestion media, with incubation at 37 °C for 30 min. The volume 
was adjusted to 10 mL with digestion media and a final concentration of 10 mM EDTA. The suspension was 
passed through a 70 µm filter into new 50 mL tube. The lipid portion was removed by centrifugation at 500 g 
for 10 min at 4 °C. Preadipocytes in the stromal vascular fraction of the pellet were isolated by treatment with 
RBC lysis buffer on ice for 5 min. Lysis was stopped with MACs buffer (PBS with 2% FBS and 1 mM EDTA). 
Preadipocytes were washed once more with PBS solution, counted and seeded on a culture plate. To induce dif-
ferentiation, the preadipocytes were treated with the adipogenic factors, 0.5 mM IBMX, 2 µg/mL dexamethasone, 
10 µM rosiglitazone and 1 µg/mL insulin, as previously described33.
RNA extraction from cells and tissues. RNA was extracted with the TRIzol reagent (Thermo Fisher 
Scientific, MA, USA), in accordance with the manufacturer’s instructions. Prior to RNA extraction, tissues were 
frozen in liquid nitrogen and ground into powder with a glass mortar.
Quantitative real-time PCR. For quantitative real-time PCR, the transcript level of genes of interest was 
measured using a StepOnePlus Real Time PCR System (Applied Biosystems, UK). Total RNA was reverse tran-
scribed into cDNA using an AccuPower® RT PreMix (Bioneer Corporation). The cDNA was used for real-time 
PCR according to the manufacturer’s guidelines, with the following modifications: PCR was performed in trip-
licate in a total volume of 20 μL 2X Power SYBR® Green PCR Master Mix(Applied Biosystems, UK) contain-
ing 200 nM final concentration of the specific primer and 1 μL cDNA. The mixture was incubated for 10 min 
at 95 °C prior to the PCR amplification, which consisted of 40 cycles of denaturation, annealing and exten-
sion. Denaturation was performed for 15 s at 95 °C, annealing was performed for 1 m at 60 °C and extension 
was performed at 72 °C for 20 s with fluorescence detection at 72 °C after each cycle. After the final cycle, the 
melting-point analysis of the samples was performed within the range of 60–95 °C with continuous fluorescence 
detection. A specific cDNA sample was included in each run and used as a reference for comparison between 
runs. The expression level of 18 s rRNA or actin or was used for normalization while calculating the expression 
levels of the other genes (as indicated in the text). Results were presented as the relative expression level of each 
gene. The primers used in this study are shown in Supplementary Table 1. To measure the relative amount of 
mRNA expression, the Δ CT value of each gene is calculated with respect to the CT values of β-actin or 18S rRNA 
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(internal control) in each sample. Next, the Δ CT value of each gene in the drug treated samples were further nor-
malized with the Δ CT value of the same gene in the non-treated HFD sample or SFD sample to calculate the ΔΔ 
CT value, indicating the relative expression of each gene in the drug treated samples compared with that of the 
controls. The relative mRNA expression fold-change was finally calculated using the 2−2ΔΔCT method. The final 
mRNA expression in each experiment is calculated as the average value of three independent set of experiments.
Western blotting. Protein was harvested from 10–30 mg tissue samples using 1 ml cold homogenization 
buffer (20 mM Tris-Cl (pH 7.4), 0.32 M sucrose and 1 mM EGTA containing protease inhibitor cocktail) and 
homogenization with a Wheaton® Potter-Elvehjem Tissue Grinder (NJ, USA). Protein was quantified using the 
Figure 11. Schematic of the consequences of ENOblock treatment on the progression of diet-induced obesity. 
In HFD mice, ENOblock treatment induces the nuclear localization of enolase and its secondary moonlighting 
activity as a transcriptional repressor. Key regulators of adiposity, gluconeogenesis and inflammatory response 
are downregulated, with a concomitant increase in adipose tissue mitochondrial membrane depolarization 
via Ucp-3 upregulation. This combined pattern of gene expression modulation inhibits the progression of 
obesity and related complications. The copyright holder (Mrs Hyunju Park) has granted permission to Springer 
Nature Limited to publish the images of the mice in Fig. 11 of the manuscript entitled “ENOblock inhibits the 
pathology of diet-induced obesity” by Cho, et al., under a CC BY open access license.
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Bradford assay. 30 to 40 μg protein samples were loaded into 10% polyacrylamide gels, and transferred to nitro-
cellulose membranes after electrophoresis. Primary antibody was used at a 1:1000 dilution in TBS-T plus 5% 
skimmed milk, and incubated with the membranes overnight at 4 °C. Primary antibody detection was performed 
with a HRP-conjugated secondary (anti-mouse IgG-HRP, sc2031, Santa Cruz Biotech, CA, USA) used at a 1: 
10000 dilution, with incubation for 30 min at room temperature. Expression signals were visualized with an ECL 
solution (RPN2232, GE Healthcare Life Science, UK). The bands were visualized using the ImageQuant LAS 500 
(GE Healthcare Life Sciences).
Measurement of mitochondrial membrane potential. Mitochondrial membrane potential in live cells 
was assessed using the TMRE probe, as previously described41. Cells were seeded in 96 well plates and treated 
with compound of interest for 72 h. Cells were then treated with 1 µM TMRE for 20 min at 37 °C. The cells were 
then washed with PBS containing 0.2% bovine serum albumin (BSA) and fluorescence was measured with a 
microplate reader (λex = 549 nm, λem = 575 nm; SpectraMax, Molecular Devices, CA, USA). For live cell imaging, 
cells were seeded in 96-well clear bottom black polystyrene microplates (Corning™, catalog no. 07-200-565) at 
a density of 5 × 103 cells and treated with compound of interest for 72 h. Cells were then treated with 200 nM 
TMRE for 20 min at 37 °C, washed with 0.2% BSA in PBS and imaged and quantified TMRE stained cells with 
a Lionheart FX automated microscope (BioTek, VT, USA). Fluorescence was measured with an excitation of 
549 nm and an emission of 575 nm (Texas-Red filter). In order to account for variations in cell location in the well 
the fluorescence was measured with a 2 × 2 area scan and the results averaged. The mean objective intensity was 
measured and normalized by cell counting in each well using Gen5TM 3.0 software (BioTek, VT, USA). Data is 
represented as the mean of 9 determinations.
Oil Red O staining. Differentiating 3T3-L1 adipocytes in 12 well culture dishes were stained with Oil Red O 
to visualize lipid accumulation using the previously published protocol80. Oil Red O staining was quantified by 
dissolving the cells in 1 mL 100% isopropanol for 5 min at room temperature with gentle rocking. 200 µL aliquots 
were transferred to a 96 well plate and absorbance was measured at λ = 492 nm (SpectraMax, Molecular Devices, 
CA, USA).
Immunocytochemistry analysis of enolase nuclear translocation. Hepatocytes were cultured in 
MultiCellTM 8B, staining chambers (CtrlBio). The enolase antibody H-300 (Santa Cruz Biotechnology sc-15343; 
1:50 dilution) was used for immunocytochemistry. Goat Anti-Rabbit IgG-heavy and light chain Antibody 
DyLight®488 Conjugated (Bethy) was the secondary antibody. Stained cells were mounted with ProLong™ Gold 
Antifade Mountant with DAPI. Images were detected using a Fluoview FV 1000 confocal laser-scanning micros-
copy with 40x magnification. Two randomly selected high-power fields were quantified from each sample of 
stained cells and averaged to obtain the value for each slide; n = 3 for each experimental group and analyzed by 
ImageJ. Nuclear enolase in the cells and their ‘Integrated Density’ was used for calculating the corrected total cell 
fluorescence (CTCF = Integrated Density - (Area of selected cell X Mean fluorescence of background readings)).
siRNA silencing of enolase expression. siRNA-mediated knockdown of enolase expression was assessed 
using qPCR. Hep G2 hepatocytes were seeded in 6 well plates at a cell density of 2 × 105 cells per well. Twenty-four 
hours after seeding, cells were transfected with 40 or 60 pmol siRNA, following the manufacturer’s protocol pro-
vided by Santa Cruz Biotechnology. Transfected cells were used for SREBP and enolase gene expression analysis 
at twenty-four hours’ post-transfection.
Chromatin Immunoprecipitation Assay. A chromatin immunoprecipitation (ChIP) assay kit was pur-
chased from Cell Signaling (CST - SimpleChIP® Enzymatic Chromatin IP Kit) and the assay was carried out follow-
ing the manufacturer’s instructions. The enolase antibody H-300 was used for the assay (Santa Cruz Biotechnology). 
Precipitated DNAs were analyzed using the following primers: SREBP1 Primers: Transcription start site (TSS) includ-
ing primer ACCTGTGCCCACTTCTTTGC and GCCAGGTGCCCAGTAAATGA; TSS non-including primer 
(down-stream) AGTGACGGCTAGGGCTCCTT and CTCTACCCATGGCGGTTCCT; TSS non-including primer 
(up-stream) CCCTCACCCCACCATTAGC and GCCAATGGAGTTTTGAAATCG. SREBP2 primers: TSS including 
primer TGAGTTTGTGATGCTCTTATGCATT and TTGGGTTGGCTTTCTTTTGG; TSS non-including primer 
(down-stream) GATCTTGGCTCACTGCAACCT and GATGTAGTGTTGCGTGCCTGTAA; TSS non-including 
primer (up-stream) CCCAAGAGACAATAAAAATCCATCA and GCATAAGAGCATCACAAACTCATGA.
Animal studies. The studies were carried out in accordance with the Institute for Laboratory Animal 
Research Guide for the Care and Use of Laboratory Animals and were approved by the Gwangju Institute of 
Science and Technology Animal Care and Use Committee (approval number: GIST-2017-079). High fat diet-fed 
male C57BL/6 J mice were purchased from Charles River, Japan. The mice had been fed the HFD from 4 weeks old 
and were supplied at 14 weeks old. After delivery, the mice continued the HFD (supplied by Jung Ahn Laboratory 
Animal, Inc., Republic of Korea). The animals were stabilized in the animal facility for 5 days and maintained in a 
12 h/12 h light cycle at a density of 3 mice per cage. The mice had free access to the HFD chow, which was weighed 
beforehand. The cages were cleaned weekly before the fasting experiment. After stabilization, the drug treatment 
regime was initiated.
For the first experiment, the mice were divided into three groups of 6 mice and treated with drug for 8 weeks, 
as follows: Group (1) 8 mg/kg rosiglitazone; Group (2) 12 mg/kg ENOblock; Group (3) vehicle alone (saline with 
10% DMSO). It should be noted that the micromolar dose for rosiglitazone is higher than ENOblock: 22.4 mM 
and 20.2 mM, respectively. Drug was administered every 24 h via intraperitoneal injection with a solution volume 
of 10 uL/g. Food intake and body weight was monitored weekly from week 1 of drug treatment. Fasted blood glu-
cose was measured at weeks 4, 6 and 8. Blood glucose was measured with a OneTouch Ultra (LifeScan, CA, USA). 
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The insulin tolerance test (ITT), glucose tolerance test (GTT) and pyruvate tolerance test (PTT) were carried 
out using the guidelines provided by the Mouse Metabolic Phenotyping Centers, Yale School of Medicine 
(MMPC; https://www.mmpc.org/). GTT, ITT and PTT was carried out after 4, 5 and 7 weeks of drug treatment, 
respectively.
For the second experiment, the HFD mice were divided into three groups, as follows: Group (1) 8 mice 
received 120 mg/kg metformin; Group (2) 7 mice received 12 mg/kg ENOblock; Group (3) 8 mice received vehi-
cle alone (saline with 10% DMSO). The selected metformin dose was based on a previously published study81. 
Drug was administered every 24 h for 8 weeks, via intraperitoneal injection with a solution volume of 10 uL/g. 
Food intake and body weight was monitored weekly from week 1 of the drug treatment. GTT, ITT and PTT were 
carried out after 4, 5 and 7 weeks of drug treatment, respectively. For the animal experiments, blinding was used 
when carrying out the GTT, ITT and PTT.
At the end of drug treatment, the mice were sacrificed by inhalation of diethyl ether. Blood was collected 
from the heart, and the kidneys, liver, brain, spleen, pancreas, skeletal muscle, gonadal adipose tissue and brown 
adipose tissue were harvested. The blood was placed in a microfuge tube and left at 15 min at room temperature 
to undergo clotting. The clot was removed using centrifugation (1500 g at 4 °C for 10 min). The supernatant was 
divided into 50 μL aliquots and frozen at −80 °C. The dissected organs and tissues were washed twice with PBS 
and stored at −80 °C.
As a short-term test to compare ENOblock and orlistat in mice fed a HFD, male C57BL/6 J mice were divided 
into three groups of 5 mice, stabilized in the animal facility for 7 days, and fed a HFD for 20 days while receiving 
the following drug regimes: (1) 10 mg/kg ENOblock by daily IP delivery; (2) 15 mg/kg orlistat by daily oral gavage; 
(3) Untreated. During the drug treatment and feeding with a HFD, the mice were assessed for body weight (at 
days 0, 4, 8 and 12), cumulative food intake (at days 4, 8, 12, 16 and 20) and fecal fat content (at days 4, 8 and 12, 
which was measured using a previously published protocol82).
Measurement of serum triglyceride. Blood samples were collected from mice and centrifuged using 
serum separation tube (BD Microtainer® SSTTM, NJ, USA). The serum samples were stored at −80 °C before 
tested. Triglyceride quantification was determined with a colorimetric Triglyceride Quantification Kit (K622- 
100; BioVision, CA, USA) in accordance with the manufacturer’s instructions. Triglyceride concentration was 
calculated and expressed as mM. Blood serum samples were used from 5 to 6 animals per treatment group in 
duplicate.
Measurement of serum HDL and LDL cholesterol. High-density lipoprotein (HDL) and low-density 
lipoprotein (LDL) cholesterols were measured with a HDL and LDL/VLDL Quantification Colorimetric/
Fluorometric Kit (catalog # K613, BioVision, Inc., USA), using the colorimetric assay. Blood serum samples were 
used from 5 animals per treatment group in duplicate.
Serum insulin quantification. Levels of insulin in the sera was measured using a mouse ELISA kit 
(Abnova, Taiwan). The serum was diluted 10-fold for the ELISA. Blood serum samples were used from 6 animals 
per treatment group.
Measurement of serum alanine aminotransferase (ALT) activity. ALT activity was expressed as 
nmol/mon/mL (=mU/mL) and the assay was carried out following the method provided by the kit (catalog 
#K752, BioVision, Inc., USA). Blood serum samples were used from 6 animals per treatment group in triplicate.
Embedding and sectioning of tissues. Tissues from the dissected mice were washed 2 times with PBS, 
blotted dry, placed into a cryo-mold and covered with OCT for embedding (Leica, Germany). Embedded tissues 
were then snap-frozen using liquid nitrogen and transferred to slurry of isopropanol. The frozen tissues were 
stored at −80 °C until sectioning using CM 1850 cryostat (Leica, Germany).
For paraffin sections, white and brown adipose tissues were formalin-fixed with 10% formaldehyde solution 
for 5 hr, and processed through paraffin embedment after dehydration and xylene-washing processes. Paraffin 
embedded blocks were sectioned at 3 μm. Sections were deparaffinized before H&E or Masson’s trichrome stain-
ing. Hematoxylin and eosin staining was carried out using a staining kit (Merck, Germany).
5 mice per treatment group were used to analyze liver fibrosis, lipid accumulation, steatosis and hepatic satel-
lite numbers. Microscopic images were captured at x200 magnification.
Measurement of lipid accumulation in liver tissue. Liver lipid accumulation was visualized using oil 
red O staining and measured with ImageJ 1.45 s software (NIH, USA). Liver tissue was sectioned at 8 μm thick-
ness, air dried for 10 minutes and fixed in 10% formalin solution. Slides were rinsed with tap water, washed with 
60% isopropanol, stained with freshly prepared oil red O staining solution (3 g/L) (Sigma-Aldrich, USA) for 
15 min, rinsed with 60% isopropanol and mounted with aqueous mountant (Sigma-Aldrich, USA). 30 randomly 
selected lipid droplets in 5 randomly captured microscope images from 5 mouse livers/treatment group were used 
for the quantification (magnification: 200x).
Measurement of liver steatosis. Steatosis was visualized using H&E staining, as previously described83. 10 
different regions of each mouse liver (magnification 200x) were used to quantify hepatic steatosis with the Image 
J software 1.48 v software (NIH, USA),
Determination of tissue fibrosis. Tissue sections were stained with Masson Trichrome Staining Kit 
(Sigma-Aldrich, USA). Fibrotic regions were quantified by detecting the blue stained area with the Image J 
software (NIH, USA), as described previously84. 8 to 10 randomly captured microscope images from sections, 
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prepared from 5 mouse livers (cryo-sectioned) or BAT (paraffin-sectioned) per treatment group were used for 
the quantification (magnification: 200x).
Detection of hepatic stellate cells. Hepatic stellate cells were detected by α-SMA staining, as previously 
described45. Stellate cells were quantified by counting α-SMA and DAPI double-labeled cells. Ten randomly cap-
tured microscope images of cryo-sections from 5 mouse livers in each treatment group was used for the quanti-
fication (magnification: 200x).
Quantification of hippocampus mitochondrial DNA. Mitochondrial DNA (mtDNA) content in the 
hippocampus was quantified using a previously published methodology54. Phenol-chloroform-isoamyl alco-
hol was used to purify DNA and 2 ng was loaded into each well of a 384-well plate with TaqMan primers for 
18S nuclear (Mm03928990_g1) or 16S mitochondrial (Mm04260181_s1) DNA (Applied Biosystems, USA). 
Hippocampus mtDNA was quantified from 6 mice in each treatment group.
Nissl staining of hippocampal neurons. Neurons in the hippocampus were visualized using a NovaUltra 
Nissl staining kit (IHC World, USA). 4 sections of the hippocampus from 6 SFD, 5 HFD, 6 rosiglitazone-treated 
and 5 ENOblock-treated HFD mice were used for staining.
Measurement of adipocyte size. Adipose tissue sections were stained with H&E and the size distribution 
of adipocytes was measured using Image J software, using a previously described method85. Gonadal adipose 
tissue from 5 mice per treatment group was stained and 100 randomly selected adipocytes were measured from 
each mouse.
Isolation of adipose tissue immune cells for flow cytometry. The isolation of immune cells from 
adipose tissue was based on the previously published protocol86. Gonadal adipose tissue was dissected from the 
sacrificed mice. After being weighed and photographed, the adipose tissue was digested in collagenase. Gonadal 
tissue from 6 mice per treatment group were used for immune cell analysis. The stromal vascular fraction pellet 
containing immune cells was suspended in FACS buffer (1X DPBS (without calcium and magnesium), 2 mM 
EDTA, and 1% FCS) and stained with antibodies against CD68 (macrosialin) and CD206 (mannose receptor). 
The populations of stained cells were analyzed with a FACS CantoII (BD Biosciences, USA) and Flowlogic soft-
ware (Miltenyi Biotech, Republic of Korea).
Statistical analysis. The Student’s t test (Microsoft Excel 2013), 1-way-ANOVA with Dunnett’s multi-
ple comparison test or 2-way-ANOVA with Tukey’s multiple comparison test (Figs 3E–G, 4A–C,G, 9C,E,G,I 
and 10A,B) as the post-test analysis (Graphad Prism version 6) was used for comparison between experimen-
tal groups, as indicated in the manuscript figure legends. p-values of <0.05 were considered significant. Unless 
otherwise stated, all results are the average of three independent experiments and the error bars are standard 
deviation.
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